Locations & Facilities

Over 189,500 sq. ft. drug substance manufacturing facility (MFG11) featuring state-of-the-art single-use technology located within The Reactory biomanufacturing park in Worcester, MA

Dedicated to biologics clinical- and commercial-scale drug substance cGMP manufacturing with total bioreactor capacity of 24,000L

Construction on track and completed weather tight, GMP operation targeted in 2025

Over 154,400 sq. ft. of laboratories and manufacturing suites located in the robust biopharmaceutical tristate region of NY, NJ and PA

Services include biologics CMC development and clinical-scale drug substance and drug product cGMP manufacturing

Site operations commenced in 2021

Drug substance manufacturing facility (MFG18) GMP release in 2022

Robotic drug product fill and cGMP manufacturing facility (DP12) operations and GMP release expected in 2024

More than 33,000 sq. ft. facility located in the Discovery Labs campus in King of Prussia (KOP), PA

Services include biologics process development and process characterization

Biosafety Level 2 laboratories

Operational since 2020

The site offers comprehensive, integrated one-stop biologics discovery, development and clinical manufacturing services in one central location

European Medicines Agency (EMA)-certified GMP cell banking suites

200,000 sq. ft. clinical drug substance manufacturing facility (MFG3) has been operational since 2018

1.6 million sq. ft. Integrated Biologics CRDMO center

The Center provides biologics discovery, development and clinical GMP manufacturing services in one location

Operational since 2021

8,000 sq. m. Biosafety Testing Center

Capabilities include cell bank characterization, unprocessed bulk harvest, virus harvest, and raw materials of animal origin release testing as well as viral clearance studies

Operational since 2022

Multiple drug substance and drug product manufacturing facilities (MFG1, MFG2, MFG4, MFG5, DP1, DP2, DP4, DP5) located in this region with a total facility footprint of 160,000 sq. m.

Capabilities include early and late-stage process development and clinical & commercial-scale drug substance and drug product GMP manufacturing

First biologics facility in China approved by the U.S. FDA and EMA for commercial manufacturing

6,000 sq. m. site dedicated to the development and GMP manufacturing of Antibody Drug Conjugates (ADCs) and other bioconjugates.

Capabilities include process development, pilot scale to large-scale cGMP manufacturing of drug substance and drug product.

GMP release of this facility commenced in 2019

Over 16,000 sq. m. Biosafety Testing Center, one of the first third-party centers for biosafety testing services in Asia

Services include cell line characterization and adventitious agent testing for the QC release of cell banks, unprocessed bulk (UPB) lots and raw materials as well as viral clearance per global regulatory guidelines.

Operational since 2014

Site contains a drug substance manufacturing facility (MFG21) and drug product fill & finish facility (DP11)

Services include process development, clinical drug substance manufacturing as well as liquid and lyophilization drug product fills

Site acquired from CMAB Biopharma Group and released for GMP manufacturing in 2021

35,000 sq. m. Biologics Integrated Innovation Center

The center serves the development and GMP manufacturing of microbial-derived products and mRNA products

Operational since 2020

The site includes drug substance manufacturing facility (MFG14) and drug product fill & finish facility (DP8), which were released for GMP manufacturing in 2022

50,400 sq. m. manufacturing site that includes a drug substance manufacturing facility (MFG20) and drug product fill & finish facilities (DP9 and DP10)

Facilities acquired from Pfizer China and were released for GMP manufacturing in 2021

314,000 sq. m. site, WuXi Biologics’ largest site in Southwest China

The Protein Science labs at this site were launched in November 2022

The initial bioreactor capacity of 48,000L for drug substance GMP manufacturing is expected to be available in 2024

82,160 sq. m. site, one of the largest biologics CRDMO sites in northern China

The site flexibly provides commercial manufacturing services at 4,000L to 20,000L scale

Drug substance manufacturing facility (MFG8) GMP release commenced in 2022

USD$1.4 billion investment over ten years to build a comprehensive CRDMO Center

The Center will provide end-to-end services from biologics research and development to large-scale drug substance and drug product GMP manufacturing

120,000 liters biomanufacturing capacity is expected to be available in 2026